EP1009404A4 - METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS - Google Patents

METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Info

Publication number
EP1009404A4
EP1009404A4 EP98922359A EP98922359A EP1009404A4 EP 1009404 A4 EP1009404 A4 EP 1009404A4 EP 98922359 A EP98922359 A EP 98922359A EP 98922359 A EP98922359 A EP 98922359A EP 1009404 A4 EP1009404 A4 EP 1009404A4
Authority
EP
European Patent Office
Prior art keywords
methods
inflammatory diseases
treating inflammation
padprt
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98922359A
Other languages
German (de)
French (fr)
Other versions
EP1009404A1 (en
Inventor
Ernest Kun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of EP1009404A1 publication Critical patent/EP1009404A1/en
Publication of EP1009404A4 publication Critical patent/EP1009404A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP98922359A 1997-05-13 1998-05-13 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS Ceased EP1009404A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US855616 1997-05-13
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors
US56396 1998-04-06
PCT/US1998/010033 WO1998051308A1 (en) 1997-05-13 1998-05-13 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Publications (2)

Publication Number Publication Date
EP1009404A1 EP1009404A1 (en) 2000-06-21
EP1009404A4 true EP1009404A4 (en) 2009-07-01

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98922359A Ceased EP1009404A4 (en) 1997-05-13 1998-05-13 METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS

Country Status (9)

Country Link
EP (1) EP1009404A4 (en)
JP (1) JP4362638B2 (en)
CN (1) CN1198614C (en)
AU (2) AU7484798A (en)
BR (1) BR9809115A (en)
CA (1) CA2289119C (en)
IL (1) IL132758A0 (en)
NZ (1) NZ501650A (en)
WO (2) WO1998051307A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (en) 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
ES2357057T3 (en) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited DERIVATIVES OF FTALAZINONA.
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (en) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010502731A (en) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
CN101641013B (en) 2007-01-22 2014-07-30 Gtx公司 Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PT2118074E (en) 2007-02-01 2014-03-20 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
KR20100059950A (en) 2007-09-14 2010-06-04 아스트라제네카 아베 Phthalazinone derivatives
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CN102238945B (en) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 Pharmaceutical formulation 514
JPWO2010061908A1 (en) 2008-11-28 2012-04-26 中外製薬株式会社 1- (2H) -Isoquinolone derivatives
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
KR101892987B1 (en) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
JP5992049B2 (en) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション Oral immediate release formulations for substituted quinazolinones
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (en) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． Novel heterocyclic compounds as bromodomain inhibitors
CN107530356A (en) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 For treating the composition and treatment method of complement-associated disease
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. Iniparib formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006687A1 (en) * 1990-10-19 1992-04-30 The Regents Of The University Of California Novel 5-iodo-6-amino-1,2-benzopyrones and their analogs useful as cytostatic and antiviral agents
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US5583155A (en) * 1989-09-26 1996-12-10 Octamer, Inc. 6-amino-1,2-benzopyrones useful for treatment of viral diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
DE4436127A1 (en) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Use of benzoic or pyridine:carboxylic acid or amide cpds.
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583155A (en) * 1989-09-26 1996-12-10 Octamer, Inc. 6-amino-1,2-benzopyrones useful for treatment of viral diseases
WO1992006687A1 (en) * 1990-10-19 1992-04-30 The Regents Of The University Of California Novel 5-iodo-6-amino-1,2-benzopyrones and their analogs useful as cytostatic and antiviral agents
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAUER P I ET AL: "REVERSION OF MALIGNANT PHENOTYPE BY 5-IODO-6-AMINO-1,2-BENZOPYRONE A NON-COVALENTLY BINDING LIGAND OF POLY(ADP-RIBOSE) POLYMERASE", BIOCHIMIE, MASSON, PARIS, FR, vol. 77, no. 5, 1 January 1995 (1995-01-01), pages 374 - 377, XP000573099, ISSN: 0300-9084 *
KR\GER H ET AL: "SYNERGISTIC EFFECTS OF THALIDOMIDE AND POLY(ADP-RIBOSE) POLYMERASE INHIBITION ON TYPE II COLLAGEN-INDUCED ARTHRITIS IN MICE", INFLAMMATION, PLENUM PRESS, NEW YORK, NY, US, vol. 20, no. 2, 1 January 1996 (1996-01-01), pages 203 - 215, XP002954235, ISSN: 0360-3997 *
KRÖGER H ET AL: "The influence of antagonists of poly(ADP-ribose)polymerase on the activity of antirheumatic drugs on the development of adjuvant arthritis in rats and on the induction of tyrosine aminotransferase in the liver of rats", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, vol. 398, 1 January 1996 (1996-01-01), pages 523 - 526, XP009116003, ISSN: 0065-2598 *
MIESEL R KURPISZ M KR\GER H: "MODULATION OF INFLAMMATORY ARTHRITIS BY INHIBITION OF POLY(ADP RIBOSE) POLYMERASE", INFLAMMATION, PLENUM PRESS, NEW YORK, NY, US, vol. 19, no. 3, 1 January 1995 (1995-01-01), pages 379 - 387, XP002954234, ISSN: 0360-3997 *
SCHRAUFSTATTER I U ET AL: "HYDROGEN PEROXIDE-INDUCED INJURY OF CELLS AND ITS PREVENTION BY INHIBITORS OF POLY-ADP-RIBOSE POLYMERASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 83, no. 13, 1986, pages 4908 - 4912, XP002526047, ISSN: 0027-8424 *
See also references of WO9851308A1 *
SZABO C ET AL: "DNA STRAND BREAKAGE, ACTIVATION OF POLY(ADP-RIBOSE) SYNTHETASE, ANDCELLULAR ENERGY DEPLETION ARE INVOLVED IN THE CYTOTOXICITY IN MACROPHAGES AND SMOOTH MUSCLE CELLS EXPOSED TO PEROXYNITRITE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 93, 1 March 1996 (1996-03-01), pages 1753 - 1758, XP000960495, ISSN: 0027-8424 *
SZABO CSABA ET AL: "Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 10, no. 6, 20 May 1997 (1997-05-20), pages 1093 - 1101, XP009116048, ISSN: 1019-6439 *
SZABO CSABA ET AL: "Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite", CIRCULATION RESEARCH, vol. 78, no. 6, 1996, pages 1051 - 1063, XP002526068, ISSN: 0009-7330 *
THIEMERMANN C ET AL: "Inhibition of the Activity of Poly(ADP Ribose) Synthetase Reduces Ischemia-Reperfusion Injury in the Heart and Skeletal Muscle", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 94, no. 2, 21 January 1997 (1997-01-21), pages 679 - 683, XP002080575, ISSN: 0027-8424 *
ZINGARELLI B ET AL: "Protective effects of nicotinamide against nitric oxide-mediated delayed vascular failure in endotoxic shock: potential involvement of polyADP ribosyl synthetase", SHOCK (PHILADELPHIA): INJURY, INFLAMMATION, AND SEPSIS: LABORATORY AND CLINICAL APPROACHES, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 5, no. 4, 1 April 1996 (1996-04-01), pages 258 - 264, XP009116150, ISSN: 1073-2322 *
ZINGARELLI BASILIA ET AL: "Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide", JOURNAL OF IMMUNOLOGY, vol. 156, no. 1, 1996, pages 350 - 358, XP002526046, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
JP4362638B2 (en) 2009-11-11
CN1261278A (en) 2000-07-26
IL132758A0 (en) 2001-03-19
BR9809115A (en) 2002-01-02
WO1998051307A1 (en) 1998-11-19
WO1998051308A1 (en) 1998-11-19
EP1009404A1 (en) 2000-06-21
CA2289119A1 (en) 1998-11-19
AU745790B2 (en) 2002-03-28
AU7492698A (en) 1998-12-08
JP2002502367A (en) 2002-01-22
CA2289119C (en) 2011-03-15
AU7484798A (en) 1998-12-08
CN1198614C (en) 2005-04-27
NZ501650A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
EP1009404A4 (en) METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
HU9603041D0 (en) Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IL128217A0 (en) Phosphatase inhibitors and methods of use thereof
EP0861092A4 (en) Therapy for cellular accumulation in chronic inflammatory diseases
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
HK1042475A1 (en) Substituted thiazoles for the treatment of inflammation
EP0971735A4 (en) Methods and compositions for treating inflammatory bowel disease
IL138871A0 (en) Flushable diaper and method
HRP950499B1 (en) Compositions and methods for treating mast-cell inflammatory condition
AU7696098A (en) Substance p inhibitors in combination with nmda-blockers for treating pain
AU7472798A (en) Cox-2 inhibitors in combination with nmda-blockers for treating pain
IL126759A0 (en) Method for treating inflammation
AU3111700A (en) Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
IL130485A0 (en) New treatment for joint inflammation
HUP9902451A3 (en) Process and device for promotion of regeneration of organized tissues
GB9816234D0 (en) Compounds for use in the treatment of inflammation
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
ZA9711548B (en) Ricin inhibitors and methods for use thereof
IL155769A0 (en) Method for the treatment of inflammation
HK1044468A1 (en) Small peptides and methods for treatment of asthma and inflammation
IL138654A0 (en) Methods and materials for treating inflammatory diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

TPAD Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOS TIPA

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20090506BHEP

Ipc: A61K 31/165 20060101ALI20090506BHEP

Ipc: A61K 31/35 20060101ALI20090506BHEP

Ipc: A61K 31/47 20060101AFI19990219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090604

17Q First examination report despatched

Effective date: 20091124

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120124